real-world data

From the Field

Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer

05/19/2022

Robert Reid, MD

Yiqiong Xie, PhD, MPH

Junxin Shi, PhD

Katrine L Wallace, PhD

Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.

Dr Wallace and colleagues...

05/19/2022

Journal of Clinical Pathways

Research Reports

Patterns and Predictors of Treatment Choice in a Real-World Cohort of Patients with Metastatic Gastric Cancer in the United States

09/22/2021

Thomas A Abrams, MD

Gary Meyer, PhD

Lisa M Hess, PhD

Sui Zhang, MS, MPP

Astra M Liepa, PharmD

Yajun Zhu, MS

Jeffrey A Meyerhardt, MD, MPH

Deborah Schrag, MD, MPH

Peter C Enzinger, MD

Charles S Fuchs

Thomas A. Abrams, MD, and colleagues examine patterns of systemic therapy administration in metastatic gastric cancer and the predictors associated with specific treatment choices.

Thomas A. Abrams, MD, and...

09/22/2021

Journal of Clinical Pathways

Videos

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma

03/12/2021

Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.

Nimira Alimohamed, MD, discusses...

03/12/2021

Journal of Clinical Pathways

News

Real-World Practice Patterns, Comorbidities in Medicare Patients With MCL

01/21/2021

Journal of Clinical Pathways

Conference Coverage

Weekly vs Biweekly Cetuximab for Metastatic Colorectal Cancer

01/19/2021

Journal of Clinical Pathways

News

Optimal Real-World Immunochemotherapy Regimen for Patients With MCL

06/25/2020

A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...

A...

06/25/2020

Journal of Clinical Pathways

News

Real-World HRU, Costs in Patients With MCL Treated With Drug Combo vs Chemoimmunotherapy

05/20/2020

Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...

...

05/20/2020

Journal of Clinical Pathways

Research in Review

Clinical Trial Efficacy Consistent with Real-World Outcomes, Study Shows

07/28/2017

JCP Editors

Researchers compared the relationship between randomized controlled clinical trial efficacy data and real-world effectiveness for oncology therapies, published in Value in Health (July-August,...

...

07/28/2017

Journal of Clinical Pathways

Real-World Data Shows Metastatic Bladder Cancer Survival Worse Than in Clinical Trials

05/31/2017

JCP Editors

Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research. Current overall survival projections for patients with...

Few...

05/31/2017

Journal of Clinical Pathways